Beaumont Financial Advisors LLC Increases Position in Johnson & Johnson (NYSE:JNJ)

Beaumont Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 126,242 shares of the company’s stock after acquiring an additional 289 shares during the period. Johnson & Johnson makes up 1.4% of Beaumont Financial Advisors LLC’s investment portfolio, making the stock its 24th largest position. Beaumont Financial Advisors LLC’s holdings in Johnson & Johnson were worth $18,257,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. MCF Advisors LLC lifted its position in shares of Johnson & Johnson by 6.0% during the 4th quarter. MCF Advisors LLC now owns 15,000 shares of the company’s stock valued at $2,169,000 after buying an additional 852 shares during the last quarter. Tide Cove Capital Partners LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $2,448,000. Octavia Wealth Advisors LLC boosted its position in Johnson & Johnson by 3.3% during the fourth quarter. Octavia Wealth Advisors LLC now owns 13,885 shares of the company’s stock worth $2,008,000 after purchasing an additional 447 shares during the period. Commons Capital LLC increased its stake in shares of Johnson & Johnson by 4.8% in the fourth quarter. Commons Capital LLC now owns 2,037 shares of the company’s stock worth $295,000 after purchasing an additional 93 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its position in shares of Johnson & Johnson by 4.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,702,574 shares of the company’s stock valued at $246,226,000 after purchasing an additional 67,629 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Barclays decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a report on Tuesday. Raymond James dropped their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday. Wells Fargo & Company dropped their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday. Finally, Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.06.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $146.76 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm’s fifty day simple moving average is $147.99 and its 200 day simple moving average is $155.98. The stock has a market cap of $353.34 billion, a P/E ratio of 22.07, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.